Zobrazeno 1 - 10
of 10
pro vyhledávání: '"El Hakim Ramadan A"'
Autor:
Abd El hakim Ramadan, Mahmoud M.A. Elsayed, Amani Elsayed, Marwa A. Fouad, Mohamed S. Mohamed, Sangmin Lee, Reda A. Mahmoud, Shereen A. Sabry, Mohammed M. Ghoneim, Ahmed H.E. Hassan, Reham A. Abd Elkarim, Amany Belal, Ahmed A. El-Shenawy
Publikováno v:
International Journal of Pharmaceutics: X, Vol 7, Iss , Pp 100232- (2024)
Diabetes mellitus (DM) is the most prevalent cause of diabetic retinopathy (DRP). DRP has been recognized for a long time as a microvascular disease. Many drugs were used to treat DRP, including vildagliptin (VLD). In addition to its hypoglycemic eff
Externí odkaz:
https://doaj.org/article/90e9c3cc813e48a999c5c8078831a32b
Publikováno v:
In Journal of Drug Delivery Science and Technology February 2021 61
Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer
Autor:
Ahmed A. El-Shenawy, Mahmoud M. A. Elsayed, Gamal M. K. Atwa, Mohammed A. S. Abourehab, Mohamed S. Mohamed, Mohammed M. Ghoneim, Reda A. Mahmoud, Shereen A. Sabry, Walid Anwar, Mohamed El-Sherbiny, Yasser A. Hassan, Amany Belal, Abd El hakim Ramadan
Publikováno v:
Pharmaceutics, Vol 15, Iss 2, p 680 (2023)
Gefitinib (GFT) is a tyrosine kinase inhibitor drug used as a first-line treatment for patients with advanced or metastatic non-small cell lung, colon, and breast cancer. GFT exhibits low solubility and hence low oral bioavailability, which restricts
Externí odkaz:
https://doaj.org/article/edf3bae5918948f491e4770af7add1d3
Autor:
Mahmoud M. A. Elsayed, Moustafa O. Aboelez, Mohamed S. Mohamed, Reda A. Mahmoud, Ahmed A. El-Shenawy, Essam A. Mahmoud, Ahmed A. Al-Karmalawy, Eman Y. Santali, Sameer Alshehri, Mahmoud Elkot Mostafa Elsadek, Mohamed A. El Hamd, Abd El hakim Ramadan
Publikováno v:
Pharmaceutics, Vol 14, Iss 8, p 1629 (2022)
Hyperlipidemia is still the leading cause of heart disease in patients with hypertension. The purpose of this study is to make rosuvastatin calcium (ROS) and atenolol (AT) bilayer tablets to treat coexisting dyslipidemia and hypertension with a singl
Externí odkaz:
https://doaj.org/article/ed3d840321ea41b296a642d297400de6
Autor:
Mahmoud M. A. Elsayed, Tarek M. Okda, Gamal M. K. Atwa, Gamal A. Omran, Atef E. Abd Elbaky, Abd El hakim Ramadan
Publikováno v:
Pharmaceutics, Vol 13, Iss 5, p 648 (2021)
Luteolin (LUT) is a natural flavonoid with low oral bioavailability with restricted clinical applications due to its low solubility. LUT shows significant anti-tumor activity in many cancer cells, including hepatocellular carcinoma (HCC). The most re
Externí odkaz:
https://doaj.org/article/1c2a726a5367469da032672fa0d79543
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Applied Pharmaceutical Science. 10:44-53
Publikováno v:
Journal of Pharmaceutical Innovation. 15:664-677
Niosomes as vesicular frameworks are novel methods of delivering a drug in a sustained manner to enhance its bioavailability and get therapeutic effect over a longer period time. This study conclusively demonstrates the preparation, characterization,
Publikováno v:
Journal of Drug Delivery Science and Technology. 61:102163
Galangin (GAL) is a flavonoid with anti-tumor activity. However, its poor solubility results in low bioavailability thus hindering its clinical application. To overcome this challenge, we have prepared niosomal vesicles by reverse-phase evaporation t
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.